High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age40+
SponsorSamsung Medical Center
About this trial
The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.
Eligibility criteria
Qualifiers
Subject must be at least 40 years of age.
Asymptomatic patients with presence of coronary calcification (Agatston Score ≥ 100)
low-density lipoproteins cholesterol (LDL-C) <190 mg/dL
Disqualifiers
Objective evidence of at least moderate inducible ischemia requiring revascularization treatment
History of cerebrovascular disease
History of coronary or peripheral arterial revascularization
Active liver disease or persistent unexplained serum transaminase elevations more than 2 times the upper limit of normal range
Trial design
Treatments tested in this trial
- Guideline directed statin therapy
- High intensity statin plus ezetimibe therapy
Treatment groups
6,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov